Standard BioTools Inc. Standard BioTools Inc.

Standard BioTools Inc.

LAB

Rank in Stocks #15923
Standard BioTools Inc., together with its subsidiaries, develops, manufactures,... Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.
Share Price
$0.57
Last synced: 2026-11-18
Market Cap
$224.33M
Change (1 day)
5.67%
Change (1 year)
-58.70%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
Earnings for Standard BioTools Inc. (LAB)
Earnings in Sep 2026 TTM: $-73.03M
According to Standard BioTools Inc.'s latest financial reports, its current earnings (TTM) are $-73.03M. In 2025 the company earned $-96.70M, an increase over its 2024 earnings of $-138.31M. The earnings shown on this page are earnings before interest and taxes, or EBIT.
Earnings history for Standard BioTools Inc. from 2006 to 2026
Earnings at the end of each year
Year Earnings Change
2026 (TTM) $-73.03M -24.48%
2025 $-96.70M -30.08%
2024 $-138.31M 86.39%
2023 $-74.20M -61.54%
2022 $-192.93M 203.06%
2021 $-63.66M 17.67%
2020 $-54.10M -18.90%
2019 $-66.71M 8.60%
2018 $-61.42M -3.73%
2017 $-63.80M -20.43%
2016 $-80.18M 46.34%
2015 $-54.79M -5.05%
2014 $-57.71M 267.90%
2013 $-15.69M -16.96%
2012 $-18.89M -15.32%
2011 $-22.30M 32.61%
2010 $-16.82M -12.30%
2009 $-19.18M -35.31%
2008 $-29.65M 16.97%
2007 $-25.35M 7.61%
2006 $-23.55M 0.00%
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$216.10M -395.90%
US
$-197.00M 169.75%
US
$-222.08M 204.09%
US
$67.24M -192.07%
US
$-110.86M 51.80%
IL

Questions about Standard BioTools Inc.'s net income

What is Standard BioTools Inc.'s net income?

Standard BioTools Inc.'s net income over the last twelve months is $-73.03M, as of Sep 2026.

What was Standard BioTools Inc.'s net income in 2025?

In 2025, Standard BioTools Inc.'s net income was $-96.70M, compared with $-138.31M in 2024.

How has Standard BioTools Inc.'s net income changed since 2020?

From 2020 to 2025, Standard BioTools Inc.'s net income was highest in 2020 ($-54.10M) and lowest in 2022 ($-192.93M).

How does Standard BioTools Inc.'s net income compare with similar companies?

Standard BioTools Inc.'s net income ($-73.03M) is higher than that of 3 of the 5 similar companies listed above. The highest among them is Sirona Dental Systems, Inc., with $216.10M.